levodopa has been researched along with budipine in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (16.67) | 18.7374 |
| 1990's | 5 (41.67) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bliesath, H; Jellinger, K | 1 |
| Fischer, R; Iizuka, J | 1 |
| Biggs, CS; Fisher, A; Starr, MS | 1 |
| Klockgether, T; Löschmann, PA; Spieker, S | 1 |
| Breit, S; Dichgans, J; Klockgether, T; Spieker, S | 1 |
| Biggs, CS; Starr, MS | 1 |
| Ghaemi, M; Rudolf, J; Schmülling, S | 1 |
| Müller, T | 1 |
| Bittkau, S; Bliesath, H; Büttner, U; Fuchs, G; Glass, J; Haller, H; Klockgether, T; Kraus, P; Lachenmayer, L; Müller, D; Müller, T; Przuntek, H; Rathay, B; Sgonina, J; Steinijans, V; Teshmar, E; Ulm, G; Volc, D | 1 |
| Ceballos-Baumann, A | 1 |
| Ludolph, A; Odin, P; Oehlwein, C; Polzer, U; Renner, R; Schüler, P; Shing, M; Storch, A; Werner, G | 1 |
| Lettow, I; Röther, J | 1 |
2 review(s) available for levodopa and budipine
| Article | Year |
|---|---|
Non-dopaminergic drug treatment of Parkinson's disease.
Topics: Adenosine; Adrenergic alpha-Antagonists; Body Weight; Cholinergic Antagonists; Homocysteine; Humans; Levodopa; Methionine; N-Methylaspartate; Parkinson Disease; Piperidines; Serotonin Receptor Agonists | 2001 |
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].
Topics: Aged; Amantadine; Antiparkinson Agents; Apomorphine; Botulinum Toxins; Catechols; Cholinesterase Inhibitors; Clinical Trials as Topic; Diagnosis, Differential; Dopamine Agents; Dopamine Agonists; Enzyme Inhibitors; Ergot Alkaloids; Family Practice; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Parkinson Disease, Secondary; Parkinsonian Disorders; Piperidines | 2003 |
6 trial(s) available for levodopa and budipine
| Article | Year |
|---|---|
Adjuvant treatment of Parksinson's disease with budipine: a double-blind trial versus placebo.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperidines | 1987 |
[Modification of Parkinson tremor by budipine. A comparative study with amantadine].
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperidines; Random Allocation | 1986 |
The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations.
Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; N-Methylaspartate; Parkinson Disease; Pilot Projects; Piperidines; Severity of Illness Index | 1999 |
Tremorlytic activity of budipine in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Double-Blind Method; Electromyography; Female; Humans; Levodopa; Male; Parkinson Disease; Piperidines; Tremor | 1999 |
Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen.
Topics: Adult; Aged; Antiparkinson Agents; Bromocriptine; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperidines; Treatment Outcome | 2002 |
Efficacy and safety of high-dose cabergoline in Parkinson's disease.
Topics: Adolescent; Adult; Aged; Amantadine; Antiparkinson Agents; Cabergoline; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Ergolines; Humans; Levodopa; Middle Aged; Nitriles; Parkinson Disease; Piperidines; Prospective Studies; Quality of Life; Selegiline; Severity of Illness Index; Treatment Outcome | 2006 |
4 other study(ies) available for levodopa and budipine
| Article | Year |
|---|---|
The antiparkinsonian drug budipine stimulates the activity of aromatic L-amino acid decarboxylase and enhances L-DOPA-induced dopamine release in rat substantia nigra.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Methyltyrosine; Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Corpus Striatum; Dopamine; Drug Synergism; Kinetics; Levodopa; Male; Microdialysis; Piperidines; Rats; Rats, Wistar; Reserpine; Substantia Nigra; Time Factors | 1998 |
Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; alpha-Methyltyrosine; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Levodopa; Male; Microdialysis; Piperidines; Rats; Rats, Wistar; Reserpine; Serotonin; Substantia Nigra; Tyrosine 3-Monooxygenase | 1999 |
Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Drug Therapy, Combination; Hallucinations; Humans; Levodopa; Male; Olanzapine; Paranoid Disorders; Parkinson Disease; Piperidines; Pirenzepine; Selegiline; Severity of Illness Index | 1999 |
[Medical treatment of Parkinson's disease in elderly and multimorbid patients].
Topics: Aged, 80 and over; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; Dopamine Agonists; Female; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Piperidines | 2014 |